SESSION 13: CAR-T CELL THERAPY
CAR-HEMATOTOX: A DISCRIMINATIVE MODEL FOR CAR T-CELL RELATED HEMATOTOXICITY IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA abstract
K. Rejeski, A. Perez, P. Sesques, C. Berger, et al.
The study authors conclude that these findings underline the strikingly high incidence of hematotoxicity after CAR T-cell therapy. The CAR-HEMATOTOX will be useful for risk-adapted management of hematotoxicity, guide prophylactic antimicrobial strategies, and identify patients for potential autologous stem cell backup.
EARLY PET RESPONSE PREDICTS OUTCOME IN LARGE B-CELL LYMPHOMA PATIENTS TREATED WITH CD19 CAR-T abstract
M. Cuadrado, T. Menne, G. Petrides, W. Osborne, et al.
The study authors conclude that their results indicate that early PET response using Deauville criteria may be used to predict the risk of CAR-T failure and to guide post-CAR-T management in lymphoma. While patients achieving early DS 1-2 remission show excellent long-term outcomes, patients with DS 3-4 might benefit from combination approaches within clinical trials to increase the chance of ongoing remission. Patients with DS 5 response had a dismal outcome in their cohort and should be regarded as primary treatment failure for which early therapeutic intervention might be warranted.
FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR-T CELLS AND ENROLLED IN DESCAR-T REGISTRY, A FRENCH REAL-LIFE DATABASE FOR CAR-T CELLS IN HEMATOLOGIC MALIGNANCIES. abstract
S. Le Gouill, E. Bachy, R. Di Blasi, G. Cartron, et al.
The study authors conclude that their first analysis from DESCAR-T registry seems to confirm CAR-T cells efficacy in real life. Updated results are presented at the meeting. Overall, 537 DLBCL patients have been registered in DESCAR-T in 13 months. This demonstrates that CAR-T cells therapy has become a key treatment for R/R DLBCL. In 2021, DESCAR-T will be extended to MCL and multiple myeloma.
EFFICACY AND SAFETY OF TISAGENLECLEUCEL (TISA-CEL) IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): PRIMARY ANALYSIS OF THE PHASE 2 ELARA TRIAL abstract
S. J. Schuster, M. Dickinson, M. Dreyling, J. Martinez-Lopez, et al.
The study authors conclude that their data demonstrate the efficacy and acceptable safety of tisagenlecleucel (tisa-cel) in patients with r/r FL, including high-risk patients after multiple lines of prior therapy, and suggest that tisa-cel may be a promising therapy for patients with r/r FL.
TRANSCEND CLL 004: PHASE 1 COHORT OF LISOCABTAGENE MARALEUCEL (LISO-CEL) COMBINED WITH IBRUTINIB (IBR) FOR PATIENTS (PTS) WITH R/R CLL/SLL abstract
W. G. Wierda, K. A. Dorritie, J. Munoz, D. M. Stephens, et al.
The study authors show with their preliminary data that lisocaptagene maraleucel (liso-cel) + ibrutinib (ibr) was associated with manageable safety, including a low incidence of grade ≥3 cytokine release syndrome and neurological events, and promising efficacy in heavily pretreated patients, who were all R/R to prior ibr, with R/R CLL/SLL. No clear difference in safety was observed between 50 × 106 (dose level [DL]1) and 100 × 106(DL2) CAR+ T cells. DL2 was selected as the dose of liso-cel when given with ibr in the ongoing expansion cohort.
OUTCOME OF LARGE B-CELL LYMPHOMA PATIENTS FAILING CD19 TARGETED CAR-T THERAPY abstract
A. Kuhnl, A. A. Kirkwood, M. O'Reilly, R. Sanderson, et al.
The study authors conclude that this large national real-world cohort demonstrates the poor outcome of lymphoma patients failing CD19 CAR-T, with almost half of patients not given further treatment.